

**Original Research Article**

## Seroprevalence of Human Immunodeficiency Virus, Hepatitis Viruses, and Co-Infections among Blood Donors at Indore, Central India

Authors

O. P. Moorjani<sup>1</sup>, Ashok Yadav<sup>2</sup>, C.S. Chhatrasal<sup>3</sup>, Shikha Ghanghoria<sup>4</sup>,  
Amrita Tripathi<sup>5</sup>, Priya Jain<sup>6</sup>

<sup>1, 2, 3,4,5,6</sup>Department of Pathology, M.G.M. Medical College & M.Y.Hospital, Indore

Corresponding Author

**Dr Amrita Tripathi**

Department of Pathology, MGM Medical College &amp; M.Y. Hospital, Indore

Email: [tripathiamrita16@gmail.com](mailto:tripathiamrita16@gmail.com)**Abstract**

**Background:** *Transfusion infectious agents such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and, hepatitis C virus (HCV) are among the greatest threats to blood safety for recipients. They are also the leading causes of death and chronic and life-threatening abnormalities.*

**Methods:** *Serological screening was performed on 42582 blood donors at the M.Y. Hospital blood bank, Indore, M.P. India between January 2008 and December 2010. We applied post-stratification weights to control for sampling bias and used logistic regression analyses to examine the association of seropositivity and co-infections with sex, age, provinces of residence, and year of blood donation.*

**Result:** *Majority of donors are voluntary donors (73.85%) and male donors (97.66%). Seroprevalence of HBV, HIV and HCV are 1.97 %, 0.185 % and 0.032 % respectively. Age group 26-35 year are show higher seroprevalence (1.023 %) for all types of transfusion transmitted disease.*

**Conclusion:** *A suitably conducted that the time and cost involved screening, notification and counseling of permanently deferred donors will help in reducing these co-infections rates.*

**Key Words:** *Blood donors, Co-infections, Hepatitis B, HIV infection.*

**Introduction**

Transmission of infectious diseases through donated blood is of concern to blood safety as transfusion forms an integral part of medical and surgical therapy. Timely transfusion of blood protects lots of lives, but unsafe transfusion practices lead lots of people to risk of transfusion infections.<sup>[1]</sup> The morbidity and mortality resulting from transfusion of infected blood have sweeping penalties, not only for the recipients themselves, but also for their families, their communities and the wider society.<sup>[2,3]</sup>

Only continuous improvement and implementation of proper donor selection, sensitive screening tests, and effective inactivation procedures can ensure the elimination, or at least reduction, of the risk of acquiring transfusion infections.<sup>[4]</sup> Transfusion infections can exist as asymptomatic disease in the hosts, so donors must be screened for high-risk behaviour related diseases. Evaluation of data on the prevalence of transfusion infections namely human immune deficiency virus (HIV), hepatitis B virus (HBV),

and hepatitis C virus (HCV) among blood and blood component donors permits an assessment of the occurrence of infections in the blood donor population and consequently the safety of the collected donations HIV, HBV and HCV co-infection has occurred as a leading cause of morbidity throughout the world.<sup>[5,6]</sup> Because of the significant burden and clinical impact of HBV in HIV-infected individuals, understanding the epidemiologic characteristics of HBV infection in HIV infected populations is vital. The prevalence of HIV infection among HBV infected persons varies markedly, from 5% -30% in different regions of the world.<sup>[7]</sup> Knowledge about burden of these diseases among healthy blood donors can provide useful information on the behaviour pattern of the general population. The present study serological screening was performed to know the co-infection rate of HIV, HBV and HCV among blood donors of our blood bank in Indore, M.P. India & the adjoining areas.

### Material and Methods

The present study is conducted in the Department of Pathology M.G.M. Medical College Indore and M.Y. Hospital blood bank. This is a retrospective study that was conducted, during the period 2008 - 2010. A total 42582 blood donors are observed in the year 2008-10 in the M.Y. Blood Bank. All voluntary or replacement blood donors who were eligible to donate blood and blood components as per the Drugs & Cosmetics act, 1940<sup>[8]</sup> and rules, 42582 who donated their blood at our blood bank during the study period were included in the study. Voluntary donations were obtained either at the blood bank or at voluntary blood bank. Replacement donors were either relatives or friends of patients. The data collected from donor register record book, donors form, master record book, HIV, HBV and HCV positive bag number records included the demographic characteristics of donors such as age, gender, residence.

### Sample Collection and Laboratory Testing

The screening for HIV was done by ELISA using kits. HBS Ag was detected by ELISA. Anti-HCV

test was done by ELISA. ABO and Rhesus (Rh) blood groups were determined using blood grouping antisera: anti-A, anti-B, anti-AB, and anti-D. Selection of cases for the study included the donors of MYH Blood Bank. For HBV, the marker used for routine screening was hepatitis B surface antigen (HBsAg). The test was performed using solid phase enzyme linked immunosorbent assay (ELISA) based on Direct Sandwich principle and the ELISA kit. For HCV, anti HCV (IgG) ELISA was performed using third generation ELISA test. The ELISA tests were performed as per the manufacturer's instructions along with validity check and incorporation of internal controls in each run. Samples positive for HBsAg antigen &/or anti HCV antibody by first test were retested by rapid test for HbsAg and HCV IgG antibodies using chromatographic immunoassay All borderline samples were tested in duplicate and if both duplicate retest sample absorbance value was less than the cut off value, the specimen was considered non-reactive. If any one of the duplicate retest absorbance value was found to be equal to or greater than the cut off, the specimen was considered to be reactive for HBsAg/HCV Ig G antibodies.

### Statistical Analysis

Data were analyzed using Chi-square test for trend to compare infection rates in consecutive 5 years. Statistical analysis was carried out using SPSS version 20 (SPSS Inc, Chicago, USA) and p-value less than 0.05 was considered statistically significant.

### Result

In the present study, 42582 blood donors are observed in the year 2008-10 in the M.Y. Blood Bank. The data collected from donor register record book, donors form, master record book, HIV, HBV and HCV positive bag number records. In observations studies, majority of donors are voluntary donors 73.85 % as compared to replacement/relative donors 26.15 %. Out of total 42582 blood donations, majority of donors are male donors 97.66 % as compared to female

donors 2.34 %. Seroprevalence of HBV, HIV and HCV are 1.97 %, 0.185 % and 0.032 % respectively. Age groups 26-35 year are showed higher seroprevalence (1.023 %) for all types of transfusion transmitted disease. for HBV-0.904 %, HIV-0.105 % (Table 1). Seroprevalence of

transfusion transmitted disease is higher in voluntary donors 62 % as compared to replacement/relative 38 % donors (Table 2).Table 3 showed the seroprevalence of co-infection is 0.04 % and it is higher for HBV with HIV infection.

**Table 1:** Overall age distribution of seroprevalence of HBV, HCV and HIV in 2008-10

| Infections | Age group (in years) |                 |                 |                | Total          |
|------------|----------------------|-----------------|-----------------|----------------|----------------|
|            | 18-25                | 26-35           | 36-45           | 46-60          |                |
| HIV        | 22<br>(0.051%)       | 45<br>(0.105%)  | 10<br>(0.023%)  | 02<br>(0.004%) | 79<br>(0.185%) |
| HBV        | 332<br>(0.779%)      | 385<br>(0.904%) | 109<br>(0.255%) | 17<br>(0.040%) | 843<br>(1.97%) |
| HCV        | 05<br>(0.011%)       | 06<br>(0.014%)  | 03<br>(0.007%)  | 00<br>(00%)    | 14<br>(0.032%) |
| Total      | 359<br>(0.843%)      | 436<br>(1.023%) | 122<br>(0.286%) | 19<br>(0.044%) | 936<br>(2.19%) |

**Table 2:** Seropositivity of transfusion transmitted diseases in total blood units collected during the year 2008-10

| Year  | Units Collected | Seropositive In total units | Voluntary donor   | Seropositive (voluntary donor) | Replacement donor | Seropositive (replacement donor) |
|-------|-----------------|-----------------------------|-------------------|--------------------------------|-------------------|----------------------------------|
| 2008  | 13052           | 281<br>(0.021%)             | 9238<br>(70.78%)  | 66<br>(0.505%)                 | 3814<br>(29.22%)  | 215<br>(1.64%)                   |
| 2009  | 14226           | 330<br>(2.13%)              | 10557<br>(74.20%) | 257<br>(1.80%)                 | 3669<br>(25.80%)  | 73<br>(0.513%)                   |
| 2010  | 15304           | 306<br>(2.00%)              | 11651<br>(76.14%) | 242<br>(1.58%)                 | 3653<br>(23.86%)  | 64<br>(0.418%)                   |
| Total | 42582           | 917<br>(2.15%)              | 31446<br>(73.84%) | 565<br>(1.32%)                 | 11136<br>(26.15%) | 352<br>(0.826%)                  |

**Table 3:** Seroprevalence of co infection with HBV, HCV and HIV

| Year  | HBV+HCV Seropositive | HBV+HIV Seropositive | HBV+HCV+HIV Seropositive | Total          |
|-------|----------------------|----------------------|--------------------------|----------------|
| 2008  | 01                   | 02                   | 02                       | 05             |
| 2009  | 00                   | 09                   | 00                       | 09             |
| 2010  | 00                   | 03                   | 00                       | 03             |
| Total | 01                   | 14                   | 02                       | 17<br>(0.040%) |

**Discussion**

The aim of this study was to determine the serological screening to know the co-infection rate of HIV, HBV and HCV among blood donors of our blood bank in Indore, M.P. India & the adjoining areas. By donor type, age, and sex and to determine association if any, in occurrence of the pathogen as well as potential risk of HBV HCV and co-infection associated with HIV seronegative blood transfusion. Majority of donors are voluntary donors 73.85 % as compared

to replacement/relative donors 26.15 %. Out of total 42582 blood donations, majority of donors are male donors 97.66 % as compared to female donors 2.34 %.which is consistent with observations in several other studies in Africa [9-11]. This study showed that 15.9%, (~one out six), of the donated blood was seropositive for at least one of the screened pathogens, which is very high prevalence that calls for strict screening of donated blood and stringent donor selection criteria[12]. These three pathogens are the

commonest in this donor population and should be always screened for as a matter of priority.

The overall Seroprevalence of HBV, HIV and HCV are 1.97 %, 0.185 % and 0.032 % respectively. These figures compared well with those reported in other parts of Africa [12-16]. Results this study when compared with those of a study conducted in 1999 at the same hospital, which found the prevalence of HIV, HBV, HCV and syphilis to be 8.7%, 11.0%, 8% and 12.7% respectively [17], represent a reduction in all the screened pathogens, especially HCV and syphilis. The reduction in HIV seem to fit a pattern reported by NACP showing a decrease of HIV infections among blood donors from 33% in 1999 to 10% in 2003 [18]. This could be due to increased self-selection of individuals donating blood, which has been associated with a reduction of number of donors per month, both replacement and voluntary donors, from 744 in 1999 to 495 in 2005 (unpublished observation), which may also explain the reduction in the seroprevalence of HBV and syphilis. It is possible that behavioural change, in particular in the youth Tanzania population, may have contributed to the observed decline in the prevalence of HIV and other STIs as suggested by others [19, 20]. The high prevalence of HCV reported in 1999 was possibly due to the latex technique used for diagnosis, which has since been found to be unreliable due cross-reactivity giving rise to false positive reactivities [17]. The current prevalence of HCV found in the present study is in keeping with findings in other parts of Africa, showing a range of between 0.2% and 3.0% [12, 21, 22].

The prevalence of Age groups 26-35 year is showed higher seroprevalence (1.023 %) for all types of transfusion transmitted disease. for HBV-0.904 %, HIV-0.105 %. Seroprevalence of transfusion transmitted disease is higher in voluntary donors 62 % as compared to replacement/relative 38 % donors. Seroprevalence showed co-infection is 0.04 % and it is higher for HBV with HIV infection. These results, which are in keeping with those of other studies [8, 9, 10], strongly indicate that replacement donors are less

suitable and that major emphasis should be made to encourage voluntary donors. It is extremely important to note the high prevalence of HBsAg (8.7), HCV (1.6%) and syphilis (4.6%) and among HIV seronegative blood, which is normally deemed, fit for transfusion. These figures, which can be utilized to estimate the risk of transfusion associated transmission HBV, HCV and co-infections, should serve as a remainder to health personnel to take the necessary precautions, including reducing the number of unnecessary transfusions [23, 24].

HBV and HIV are the most prevalent transfusion-transmissible diseases among blood donors in Indore. Screening and better selection of donors are necessary to improve blood safety in the regional blood transfusion center of M. Y. Hospital. Therefore, it is conducted that the time and cost involved screening, notification and counseling of permanently deferred donors will help in reducing these co-infections rates.

**Acknowledgment:** We are grateful to the staff at the Blood Transfusion Center, M.Y. Hospital, Indore and to all participants who contributed their blood samples.

**Conflict of Interests:** There was no conflict of interests with respect to all authors.

**Funding:** Self-funded

## References

1. Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion-transmitted infections. *J Transl Med* 2007; 5:25.
2. World Health organization. Regional office for Africa. Blood safety: a strategy for the African region. Procedural decisions and resolutions. Final report. Fifty first session of WHO regional committee for Africa. WHO AFR /RC51/9 Rev.1 Brazzaville: World Health Organization, Regional Office for Africa; 2001; 7.
3. Tapko JB, Sam O, Diarra-Nama AJ. Status of blood safety in the WHO African Region: report of the 2004 survey.

- Brazzaville: WHO Regional Office for Africa. 2007;1-25.
4. Tiwari BR, Ghimmire P, Karki S, Raj Kumar M. Seroprevalence of human immunodeficiency virus in Nepalese blood donors: A study from three regional blood transfusion services. *Asian J TransfusSci* 2008; 2:66-8.
  5. Rockstroh JK. Influence of viral hepatitis on HIV infection. *J Hepatol* 2006;44(1):525-7
  6. Jones R, Dunning J, Nelson M. HIV and hepatitis C co-infection. *Int J ClinPract* 2005; 59:1082-7.
  7. Thio CL: Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. *Semin Liver Dis* 2003; 23:125-36.
  8. Malik V. Law relating to drugs and cosmetics. 22nd edition, Lucknow: Eastern Book Company.2011.
  9. Adjei AA, Kudzi W, Armah H, Adiku T, Amoah AG, Ansah J: Prevalence of antibodies to syphilis among blood donors in Accra, Ghana. *Jpn J Infect Dis.* 2003, 56: 165-167.
  10. Madhava V, Burgess C, Drucker E: Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. *Lancet Infect Dis.* 2002, 2: 293-302.
  11. Jacob B, Mayaud P, Changalucha J, Todd J, Ka-Gina G, Grosskurth H, Berege ZA: Sexual transmission of hepatitis B in Mwanza, Tanzania. *Sex Transm Dis.* 1997, 24: 121-126.
  12. Ampofo W, Nii-Treb N, Ansah J, et al: Prevalence of blood-borne infectious diseases in blood donors in Ghana. *J ClinMicrobiol.* 2002, 40: 3523-3525.
  13. Mbanya DN, Takam D, Ndumbe PM: Serological findings among first time blood donors in Younde Cameroon. *Transfus Med.* 2003, 13: 267-273.
  14. Candotti D, Mundy C, Kadeweile G, Nkhoma W, Bates I, Allain JP: Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of hepatitis B and C viruses. *Med Virol.* 2001, 65: 1-5.
  15. Oronsaye FE, Oronsaye JI: Prevalence of HIV-positives and hepatitis B surface antigen-positives among donors in the University of Benin Teaching Hospital, Nigeria. *Trop Doct.* 2004, 34: 159-60.
  16. Uneke CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH: Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. *MemInstOswaldo Cruz.* 2005, 100: 13-16.
  17. Matee MI, Lyamuya EF, Mbena EC, Magessa PM, Sufi J, Marwa GJ, Mwasulama OJ, Mbwana J: Prevalence of transfusion-associated viral infections and syphilis among blood donors in Muhimbili Medical Centre in Dar es Salaam, Tanzania. *East Afr Med J.* 1999, 76: 167-1671.
  18. The United Republic of Tanzania. Ministry of Health. Tanzania Mainland. National AIDS Control programme. HIV/AIDS/STI surveillance. January to December, 2002. Report no. 17. 2003
  19. Kwesigabo G, Killewo JZ, Urassa W, Mbena E, Mhalu F, Lugalla JL, Godoy C, Biberfeld G, Emmelin M, Wall S, Sandstrom A: Monitoring of HIV-1 infection prevalence and trends in the general population using pregnant women as a sentinel population: 9 years experience from the Kagera region of Tanzania. *J Acquir Immune DeficSyndr.* 2000, 15: 410-7.
  20. Kwesigabo G, Killewo J, Godoy C, Urassa W, Mbena E, Mhalu F, Biberfeld G, Wall S, Sandstrom A: Decline in the prevalence of HIV-1 infection in young women in the Kagera region of Tanzania. *J Acquir Immune DeficSyndr Hum Retrovirol.* 1998, 17: 262-8.

21. Dokekias AE, Okandze-Elenga JP, Kinkouna AG, Lepfoundzou AB, Garcia S: Seroprevalence of viral hepatitis C in Brazzaville, Congo. *Bull SocPatholExot.* 2003, 96: 279-282.
22. Kallestrup P, Zinyama R, Gomo E, et al: Low prevalence of hepatitis C virus antibodies in HIV-endemic area of Zimbabwe support sexual transmission as the major route of HIV transmission in Africa. *AIDS.* 2003, 17: 1400-1402.
23. Gumodoka B, Vos J, Kigadye FC, van Asten H, Dolmans WM, Borgdorff MW: Blood transfusion practices in Mwanza Region, Tanzania. Bugando Medical Centre. *AIDS.* 1993, 7: 387-392.
24. Vos J, Gumodoka B, van Asten HA, Berege ZA, Dolmans WM, Borgdorff MW: Changes in blood transfusion practices after the introduction of consensus guidelines in Mwanza region, Tanzania. *AIDS.* 1994, 8: 1135-1140.